Lycopodium entered this result with its stock already on a strong run, up about 69% over the past three months and at A$21.35 by Wednesday’s close. Expectations were high. The headline from the earnings print is simple: the company delivered record full year revenue of A$377.5m and net profit after tax of A$40.2m, with profit margins around 10.6%, backed by a strong cash balance of A$106.2m and minimal debt.
Is Lycopodium at A$21.35 trading at a genuine discount to its cash flow potential, or does the margin pressure tell a different story? Compare that record A$40.2m profit against our valuation analysis for Lycopodium
FY 2026 Earnings Summary
- Revenue (FY 2026 vs. FY 2025): A$377.5m vs. A$341.6m (up about 11%)
- Net Profit After Tax, NPAT, (FY 2026 vs. FY 2025): A$40.2m vs. A$42.2m (down from last year)
- Basic EPS (FY 2026 vs. FY 2025): A$1.01 per share vs. A$1.06 per share (down from last year)
- Net Profit Margin (FY 2026 vs. FY 2025): 10.6% vs. 12.6% (margin compressed over the year)
Prefer clean visuals instead of another wall of Lycopodium numbers and margin figures? See a complete view of the company, including its recent profit performance, in an easy chart-driven format through our company report for Lycopodium.
Lycopodium bull story meets key conversion tests
Bulls argue Lycopodium is a cash generative, capital light project house that can turn a broad studies pipeline into recurring, double digit NPAT margins. The latest year supports parts of that story. Record A$377.5m revenue and A$40.2m NPAT keep margins around the 10% mark that management targets. The company managed more than 9 million man hours across 50+ projects and 90 studies, with the study count more than doubling since December. That suggests the front end funnel is filling. Early FY27 guidance, with A$540m to A$580m revenue and A$54m to A$58m NPAT and already A$661m of committed contracts, shows conversion from studies into execution is happening. Americas expansion also passed an early test with the first full EPCM in South America and new offices now contributing to a larger addressable market.
Margin pressure and timing risks temper Lycopodium optimism
Bears focus on margin compression, project timing risk and the possibility that headcount and office expansion run ahead of utilisation. NPAT of A$40.2m is lower than last year’s A$42.2m and basic EPS slipped from A$1.06 to A$1.01. Net profit margin moved from 12.6% to 10.6%. That indicates the company needed record revenue and a bigger workforce of about 1,500 people to hold its targeted earnings level. Management itself points to execution risk on large EPCM work such as Blackwater Phase 2 and to sanction risk on studies that are not yet converted. The Americas build out is still early. SAXUM and new Lima and Vancouver offices are helping win work, but the return on that extra capacity still depends on sustained study conversion and high utilisation through FY27 and beyond.
With margins slipping and headcount rising, are Lycopodium’s A$106.2m cash pile and minimal debt really enough if project timing turns against it? Verify the balance sheet cushion using the financial health analysis of Lycopodium stock.Take Control Of Your Next Move
If Lycopodium’s record revenue, margin shifts and growing project pipeline have your attention, register for free with Simply Wall St and add it to your Watchlist to track share price against fair value and watch how new contracts and margins develop. Once you are invested, use the Portfolio Command Center to cut through market noise and surface the key updates that matter for your holdings. For a longer term view, lean on the Community to see how other investors are thinking about risks, catalysts and turning points. By spotting potential shifts in earnings quality, cash flow and balance sheet strength early, you can stay informed and make more considered decisions.
Seeking Alternatives Beyond Lycopodium?
Fresh stock ideas can move from quiet to breakout while you watch from the sidelines. Scan these under the radar opportunities before momentum is fully caught by the crowd and act now.
- Spot potential income workhorses early and review carefully selected companies in the 6 dividend fortresses while yields are still holding up and prices have not fully priced in the payouts.
- Ride the next leg of AI momentum by checking companies in the 56 AI infrastructure stocks before spending accelerates and valuations shift away from what currently looks reasonable.
- Hunt for financial resilience and study stocks in the list of solid balance sheet and fundamentals stocks (21 results) before stronger balance sheets get fully recognised and weaker peers start dropping out of contention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com